Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

by · The Cerbat Gem

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares of the company’s stock, valued at $6,271,959.42. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Meredith Cook also recently made the following trade(s):

  • On Friday, December 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.32, for a total transaction of $32,928.00.
  • On Thursday, November 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $87.27, for a total transaction of $34,908.00.

ANI Pharmaceuticals Stock Performance

ANIP stock traded up $2.75 during trading on Wednesday, hitting $85.03. The company had a trading volume of 522,754 shares, compared to its average volume of 634,106. The firm has a market cap of $1.91 billion, a PE ratio of 52.17 and a beta of 0.51. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The firm has a 50-day moving average price of $82.37 and a 200-day moving average price of $83.54. ANI Pharmaceuticals, Inc. has a 1-year low of $54.10 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same period last year, the company earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIP has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. HC Wainwright raised their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial increased their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

Read Our Latest Report on ANIP

Institutional Trading of ANI Pharmaceuticals

Large investors have recently modified their holdings of the business. Global Alpha Capital Management Ltd. lifted its stake in ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after buying an additional 126,500 shares in the last quarter. UBS Group AG raised its holdings in shares of ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $32,992,000. Rubric Capital Management LP boosted its stake in shares of ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after acquiring an additional 85,745 shares during the last quarter. Finally, Balyasny Asset Management L.P. boosted its stake in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Further Reading